MMA Testing for Macrocytic, Hyperchromic Anemia
MMA testing should be reserved as a second-line confirmatory test only when initial B12 levels fall in the indeterminate range (180-350 ng/L for total B12 or 25-70 pmol/L for active B12) in patients with macrocytic anemia and clinical symptoms of B12 deficiency 1.
Testing Algorithm
First-Line Approach
Start with either total B12 (serum cobalamin) or active B12 (serum holotranscobalamin) as your initial test 1. The 2024 NICE guidelines emphasize that either test is acceptable, though active B12 is theoretically more accurate as it measures the biologically active form. However, the cost difference (£18 vs £2) and lack of strong evidence supporting superiority means total B12 remains a reasonable first choice in most settings.
When to Order MMA
Order MMA testing only in these specific scenarios:
- Indeterminate B12 results (180-350 ng/L total B12 or 25-70 pmol/L active B12) AND clinical symptoms/signs of B12 deficiency present 1
- Suspected nitrous oxide-related B12 deficiency 1
- When MCV >120 fL with high suspicion for B12 deficiency 2
Interpreting Results
Do NOT order MMA if:
- Total B12 <180 ng/L (133 pmol/L) — this confirms B12 deficiency, proceed to treatment 1
- Total B12 >350 ng/L (258 pmol/L) — B12 deficiency unlikely, look for other causes 1
MMA cutoffs for diagnosis:
- MMA >376 nmol/L has >99% specificity with 54.9% sensitivity for B12 deficiency 3
- MMA >229 nmol/L provides better sensitivity (80%) for screening higher-risk populations 3
- Historical studies show MMA >20 μg/mL (or >40 mg/24hr after valine load) indicates B12 deficiency 4, 5
Clinical Context and Pitfalls
Why MMA is not first-line: Despite being a more accurate functional marker of tissue B12 status 1, MMA testing is expensive (£11-80 per test), requires specialized equipment, involves external laboratory referral with delayed turnaround times, and is unnecessary when B12 levels are clearly low or normal 1.
Cost-effectiveness consideration: The 2024 NICE guideline's cost-utility analysis showed MMA testing in the indeterminate range is cost-effective at £3,946 per QALY gained 1. However, this assumes patients return for follow-up and may overestimate savings due to modeling uncertainties.
Macrocytic anemia differential: Remember that in hospitalized patients, drugs and alcohol are the most common causes of macrocytosis, followed by liver disease and reticulocytosis — megaloblastic anemia accounts for <10% of cases 2. Only pursue MMA testing if B12 deficiency remains a genuine diagnostic consideration after initial B12 testing.
Neurological symptoms matter: Patients with neurological manifestations of B12 deficiency excrete significantly higher amounts of MMA 6, making MMA particularly useful when neurologic symptoms are present with borderline B12 levels.
Renal function caveat: MMA is renally cleared, so elevated levels can occur with renal insufficiency independent of B12 status. Ensure normal renal function before interpreting MMA results 3.
Practical Implementation
The 2024 audit following NICE guideline publication showed MMA testing nearly doubled but became much more appropriate (79% meeting criteria post-guideline vs 47% pre-guideline), with increased diagnostic yield (21% vs 16% diagnosed with B12 deficiency) 7. This validates the selective use strategy rather than routine MMA testing for all macrocytic anemias.